Use of human glandular kallikrein 2 for the detection of prostate cancer: Preliminary analysis

Urology

Volumn 54, Issue 5, 1999, Pages 839-845

  Partin, Alan W ^a   Catalona, William J ^b   Finlay, Judith A ^c   Darte, Claude ^c   Tindall, Donald J ^d   Young, Charles Y F ^d   Klee, George G ^d   Chan, Daniel W ^a   Rittenhouse, Harry G ^c   Wolfert, Robert L ^c   Woodrum, David L ^c  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Hybritech Incorporated   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TISSUE KALLIKREIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

AGED; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TISSUE KALLIKREINS;

EID: 0032721585     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00270-8     Document Type: Article

References (30)

1. Cooner W.H., Mosley B.R., Rutherford C.L. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol. 143:1990;1146-1152.
2. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 324:1991;1156-1161.
3. Brawer M.K., Beatie J., Wener M.H. Screening for prostatic carcinoma with prostate specific antigen results of the second year . J Urol. 150:1993;106-109.
4. Labrie F., Dupont A., Suburu R., et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol. 147:1992;846-851.
5. Catalona W.J., Richie J.P., Ahmann F.R., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer results of a multicenter clinical trial of 6,630 men . J Urol. 151:1994;1283-1290.
6. Partin A.W., Kattan M.W., Subong E.N.P., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer - a multi-institutional update. JAMA. 277:1997;1445-1451.
7. Pound C.R., Partin A.W., Epstein J.I. PSA following anatomical radical retropubic prostatectomy patterns of recurrence and cancer control . Urol Clin North Am. 24:1997;395-406.
8. Christensson A., Bjork T., Nilsson O., et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol. 150:1993;100-105.
9. Luderer A.A., Chen Y.-T., Soriano T.F., et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology. 46:1995;187-194.
10. Catalona W.J., Smith D.S., Wolfert R.L., et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 274:1995;1214-1220.
11. Woodrum D.L., Brawer M.K., Partin A.W., et al. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol. 159:1998;5-12.
12. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. A prospective multicenter clinical trial. JAMA. 279:1998;1542-1547.
13. Catalona W.J., Smith D.S., Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination enhancement of specificity with free PSA measurements . JAMA. 277:1998;1452-1455.
14. Van Cangh P.J., De Nayer P., De Vischer L., et al. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1 8 to 10 ng/ml total PSA . Urology. 48:1996;67-70.
15. Dube J.Y., Tremblay R.R. Biochemistry and potential roles of prostatic kallikrein hK2. Mol Urol. 1:1997;279-285.
16. Rittenhouse H.G., Finlay J.A., Mikolajczyk S.D., et al. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA) two closely related, but distinct, kallikreins in the prostate . Crit Rev Clin Lab Sci. 35:1998;275-368.
17. Takayama T.K., Fujikawa K., Davie E.W. Characterization of the precursor of prostate-specific antigen - activation by trypsin and by human glandular kallikrein. J Bio Chem. 272:1997;21582-21588.
18. Lovgren J., Rajakoski K., Karp M., et al. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun. 238:1997;549-555.
19. Kumar A., Mikolajczyk S.D., Goel A.S., et al. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. 57:1997;3111-3114.
20. Piironen T., Lovgren J., Karp M., et al. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem. 42:1996;1034-1041.
21. Grauer L.S., Finlay J.A., Mikolajczyk S.D., et al. Detection of human glandular kallikrein, hK2 as its precursor form and in complex with protease inhibitors in prostate carcinoma serum. J Androl. 19:1998;407-411.
22. Darson M.F., Pacelli A., Roche P.C., et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma a novel prostate cancer marker . Urology. 49:1997;857-862.
23. Tremblay R.R., Deperthes D., Têtu B., et al. Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors. Am J Pathol. 150:1997;455-459.
24. Woodrum D.L., French C.M., Hill T.M., et al. Analytical performance of the Tandem(R)-R free PSA immunoassay measuring free prostate-specific antigen. Clin Chem. 43:1997;1203-1208.
25. Finlay J.A., Evans C., Day J.R., et al. Development of monoclonal antibodies specific for human glandular kallikrein (hK2) development of a dual antibody immunoassay for hK2 with negligible prostate specific antigen cross-reactivity . Urology. 51:1998;804-809.
26. Mikolajczyk S.D., Millar L.S., Kumar A., et al. Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors. Prostate. 34:1998;44-50.
27. Catalona W.J., Richie J.P., Ahmann F.R., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer results of a multicenter clinical trial of 6,630 men . J Urol. 151:1994;1283-1290.
28. Keetch D.W., Catalona W.J., Smith D.S. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol. 151:1994;1571-1574.
29. Partin A.W., Catalona W.J., Southwick P.C., et al. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection influence of total PSA, prostate volume, and age . Urology. 48:1996;55-61.
30. Kwiatkowski M., Recker F., Piironen T., et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology. 52:1998;360-365.